Senzime AB (publ) (SEZI) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning. Welcome to the presentation of our second quarter, 2026 report here in the midst of Swedish summertime. So the second quarter, a quarter characterized by continued strong growth for our sensors utilization, but continued market headwinds for new monitor sales, specifically in the US market. So US market has continued to be challenging for us over the last six months. I do note an improvement. But in parallel to this, we've been working diligently on the fundamentals and I'm happy to report that we have a 15% decrease in our operating expenses. We are reporting 27% improvement in our EBITDA and we're reporting a 46% improvement in our cash flow. And this is despite pretty much a zero growth quarter. So let me come back a little bit more on the numbers and a little bit the background of the business. Okay, so I wanted to comment on the recent announcement of our partnership with Philips. So I'm extremely pleased to announce this. This is the most important commercial agreement that we've signed so far. I would say it's the result of over 10 years of work. It's the result of our investments in innovation, in clinical and in market access. What we are planning to do is to jointly develop a portfolio of products based on each of our proprietary technologies. We will be driving the development and manufacturing. These will be our products and exactly what we are to develop and what to launch that remains confidential until it comes out to market. This is an extremely strong validation of our technology. We're partnering with the global leader in patient monitoring and also one of the global leaders as a medical device company. What it does is that it significantly expands our market reach. It will expand our reach way, way beyond the markets we are in today. ...